Stripey的个人主页 - 老虎社区

Stripey

暂无个人介绍

IP属地：未知

14关注

4粉丝

0主题

0勋章

2021-12-30

Failed stock and company. Can't even do a buy back.

DiDi Stock Dropped 2% in Premarket Trading

2021-12-27

Tell they you this when they need you to line up on the buy queue

JPMorgan Says Investors Too Bearish, Doesn’t See Stock Selloff

2021-12-14

Contradicting news. One article says there is effect and another no

Pfizer slid in premarket trading as Oxford study found two vaccine doses wouldn’t protect from Omicron infection

2021-12-10

$AMC 20220121 31.0 PUT$ CEO dumping and telling apes he is just only planning for his future.

2021-12-06

Yes only a few companies are having insider buys. The overall market might still drop.

Insider buying says a Santa Claus rally is on the way -- here are 10 stocks they favor

2021-12-01

$SAVA 20211217 55.0 PUT(SAVA)$From last night's dip

2021-11-25

$CHINA EAST EDU(00667)$Coming back alive again!

2021-11-25

$AMC 20220121 40.0 PUT(AMC)$Earn a little from the drop

2021-11-23

$PROG 20220121 7.5 PUT(PROG)$First round. Hoping to try the next round again.

2021-11-16

$SAVA 20220121 50.0 PUT(SAVA)$Will exit for now. Probably will drop more or a crazy short squeeze might come.

2021-11-09

$BioNTech SE(BNTX)$Hope this isn't a dead cat bounce

2021-11-07

Part of the drop is due to Pfizer's announcement of their new covid 19 pill

Why This Number in Moderna's Earnings Report Isn't as Bad as It Looks

2021-11-03

$CHINA EAST EDU(00667)$For two days the price make a full bounce![思考]

2021-10-29

$TIGR 20220121 5.0 PUT(TIGR)$Feel sad the stock of my favourite broker is going down.

2021-10-27

$CHINA EAST EDU(00667)$Good times don't last...never sell at $10. Now time to add instead.

2021-10-21

Jack had a good and long discussion and now time for his company to rise up to fair valuation. I don't think China will handicap the companies that will help it succeed.

抱歉，原内容已删除

2021-10-15

$CHINA EAST EDU(00667)$Should have stuck with my plan to add more at 7.60

2021-10-14

$Tiger Brokers(TIGR)$ The hammer is coming!Reuters news says: Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website

2021-10-09

Will the demand still be around by the time they start selling?

Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing

2021-10-09

Miss it at $30

ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4096341081825100,"uuid":"4096341081825100","gmtCreate":1633262690982,"gmtModify":1633262690982,"name":"Stripey","pinyin":"stripey","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":14,"tweetSize":23,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.29","exceedPercentage":"80.21%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.02","exceedPercentage":"81.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692114821,"gmtCreate":1640874175584,"gmtModify":1640874175668,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Failed stock and company. Can't even do a buy back.","listText":"Failed stock and company. Can't even do a buy back.","text":"Failed stock and company. Can't even do a buy back.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692114821","repostId":"1183919949","repostType":4,"repost":{"id":"1183919949","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640854650,"share":"https://www.laohu8.com/m/news/1183919949?lang=&edition=full","pubTime":"2021-12-30 16:57","market":"us","language":"en","title":"DiDi Stock Dropped 2% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1183919949","media":"Tiger Newspress","summary":"DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareho","content":"<html><head></head><body><p>DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareholders of RMB 30.6B (US$4.7B) in its Q3 earning report.</p><p><img src=\"https://static.tigerbbs.com/ce293b188578845e5e6bf0ebc79dc772\" tg-width=\"1129\" tg-height=\"716\" referrerpolicy=\"no-referrer\"/>DiDi Q3 adjusted EBITA was a loss of RMB 7.5B (US$1.2B), after posting Q2 adjusted EBITDA loss of RMB 2.3B.</p><p>Core platform transactions for Q3 were 2.86B vs. 3.00B in Q2, with transactions for its China Mobility segment at 2.36B vs. 2.57B in the prior quarter. Transactions for the International segment were 499M.</p><p>Q3 core platform gross transaction value reached RMB 68.7B (US$10.7B), down from $MB73.3B in Q2; GTV from the China Mobility segment of RMB 58.4B (US$9.1B) slipped from RMB 64.6B in Q2.</p><p>Q3 total revenue of RMB 42.7B (US$6.6B), dropped from RMB 48.2B in Q2, with revenue from China Mobility at RMB 39.0B (US$6.1B) vs. RMB 44.8B in Q2 2021.</p><p>The company also said it will schedule a shareholders meeting for a vote on choosing another internationally recognized stock exchange for listing shares that will convert from its ADSs, which now trade on the NYSE. On Dec. 3, DiDi&#39;s (DIDI) board said it would delist its ADSs from the NYSE.</p><p>The company also announced changes to its board.DiDi (DIDI) ADSsrise 1.1% in after-hours trading in New York.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiDi Stock Dropped 2% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiDi Stock Dropped 2% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-30 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareholders of RMB 30.6B (US$4.7B) in its Q3 earning report.</p><p><img src=\"https://static.tigerbbs.com/ce293b188578845e5e6bf0ebc79dc772\" tg-width=\"1129\" tg-height=\"716\" referrerpolicy=\"no-referrer\"/>DiDi Q3 adjusted EBITA was a loss of RMB 7.5B (US$1.2B), after posting Q2 adjusted EBITDA loss of RMB 2.3B.</p><p>Core platform transactions for Q3 were 2.86B vs. 3.00B in Q2, with transactions for its China Mobility segment at 2.36B vs. 2.57B in the prior quarter. Transactions for the International segment were 499M.</p><p>Q3 core platform gross transaction value reached RMB 68.7B (US$10.7B), down from $MB73.3B in Q2; GTV from the China Mobility segment of RMB 58.4B (US$9.1B) slipped from RMB 64.6B in Q2.</p><p>Q3 total revenue of RMB 42.7B (US$6.6B), dropped from RMB 48.2B in Q2, with revenue from China Mobility at RMB 39.0B (US$6.1B) vs. RMB 44.8B in Q2 2021.</p><p>The company also said it will schedule a shareholders meeting for a vote on choosing another internationally recognized stock exchange for listing shares that will convert from its ADSs, which now trade on the NYSE. On Dec. 3, DiDi&#39;s (DIDI) board said it would delist its ADSs from the NYSE.</p><p>The company also announced changes to its board.DiDi (DIDI) ADSsrise 1.1% in after-hours trading in New York.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183919949","content_text":"DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareholders of RMB 30.6B (US$4.7B) in its Q3 earning report.DiDi Q3 adjusted EBITA was a loss of RMB 7.5B (US$1.2B), after posting Q2 adjusted EBITDA loss of RMB 2.3B.Core platform transactions for Q3 were 2.86B vs. 3.00B in Q2, with transactions for its China Mobility segment at 2.36B vs. 2.57B in the prior quarter. Transactions for the International segment were 499M.Q3 core platform gross transaction value reached RMB 68.7B (US$10.7B), down from $MB73.3B in Q2; GTV from the China Mobility segment of RMB 58.4B (US$9.1B) slipped from RMB 64.6B in Q2.Q3 total revenue of RMB 42.7B (US$6.6B), dropped from RMB 48.2B in Q2, with revenue from China Mobility at RMB 39.0B (US$6.1B) vs. RMB 44.8B in Q2 2021.The company also said it will schedule a shareholders meeting for a vote on choosing another internationally recognized stock exchange for listing shares that will convert from its ADSs, which now trade on the NYSE. On Dec. 3, DiDi's (DIDI) board said it would delist its ADSs from the NYSE.The company also announced changes to its board.DiDi (DIDI) ADSsrise 1.1% in after-hours trading in New York.","news_type":1},"isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696978300,"gmtCreate":1640611889610,"gmtModify":1640611889703,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Tell they you this when they need you to line up on the buy queue","listText":"Tell they you this when they need you to line up on the buy queue","text":"Tell they you this when they need you to line up on the buy queue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696978300","repostId":"1169825066","repostType":2,"repost":{"id":"1169825066","pubTimestamp":1640606336,"share":"https://www.laohu8.com/m/news/1169825066?lang=&edition=full","pubTime":"2021-12-27 19:58","market":"us","language":"en","title":"JPMorgan Says Investors Too Bearish, Doesn’t See Stock Selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=1169825066","media":"Bloomberg","summary":"Strategists say market concentration doesn’t indicate peak\nU.S. rally may become broader in January,","content":"<ul>\n <li>Strategists say market concentration doesn’t indicate peak</li>\n <li>U.S. rally may become broader in January, according to note</li>\n</ul>\n<p>There’s no reason to fear that the rally that catapulted U.S. stocks to successive records this year will end anytime soon, according to JPMorgan Chase &amp; Co. strategists. In fact, more investors may soon join.</p>\n<p>“Conditions for a large selloff are not in place right now given already low investor positioning, record buybacks, limited systematic amplifiers, and positive January seasonals,” the strategists led by Dubravko Lakos-Bujas wrote in a note to clients. “Investor positioning is too bearish -- the market has taken the hawkish central bank and bearish omicron narratives too far.”</p>\n<p>While the S&amp;P 500 climbed to yet another record high last week, the rally has been increasingly driven by a narrow group of mega-cap companies, which is reminiscent of the bubble in tech stocks at the turn of the century. With the economic rebound following the pandemic-induced slump now past its peak, some fund managers have warned that the next stage in the cycle is a&nbsp;correction, as central banks and governments wind down stimulus measures to tame surging inflation.</p>\n<p><img src=\"https://static.tigerbbs.com/70927f00fd2b34d5345dd03f72195d1f\" tg-width=\"976\" tg-height=\"550\" width=\"100%\" height=\"auto\"></p>\n<p>For JPMorgan strategists, however, the “extreme stock dispersion and record concentration within equities” is an indicator of an abundance of caution, not a looming selloff. Investors have been treating mega caps as safe-havens, or “pseudo-bonds,” the strategists wrote.</p>\n<p>If anything, the drawdown in smaller companies offers investors attractive entry points for “reopening stocks”, such as travel and hospitality, as well as energy and e-commerce, as inflation normalizes and concerns over the Fed’s hawkishness abate, the strategists said.</p>\n<p>The bullish outlook echoes the one of Goldman Sachs Group Inc. strategists, who also said earlier this month that the narrowing rally doesn’t point to an imminent&nbsp;major drawdown.</p>\n<p>“Rising concentration is not a reliable indicator for market peaks,” JPMorgan strategists said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan Says Investors Too Bearish, Doesn’t See Stock Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan Says Investors Too Bearish, Doesn’t See Stock Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-27/jpmorgan-says-investors-too-bearish-doesn-t-see-stock-selloff?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Strategists say market concentration doesn’t indicate peak\nU.S. rally may become broader in January, according to note\n\nThere’s no reason to fear that the rally that catapulted U.S. stocks to ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-27/jpmorgan-says-investors-too-bearish-doesn-t-see-stock-selloff?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-27/jpmorgan-says-investors-too-bearish-doesn-t-see-stock-selloff?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169825066","content_text":"Strategists say market concentration doesn’t indicate peak\nU.S. rally may become broader in January, according to note\n\nThere’s no reason to fear that the rally that catapulted U.S. stocks to successive records this year will end anytime soon, according to JPMorgan Chase & Co. strategists. In fact, more investors may soon join.\n“Conditions for a large selloff are not in place right now given already low investor positioning, record buybacks, limited systematic amplifiers, and positive January seasonals,” the strategists led by Dubravko Lakos-Bujas wrote in a note to clients. “Investor positioning is too bearish -- the market has taken the hawkish central bank and bearish omicron narratives too far.”\nWhile the S&P 500 climbed to yet another record high last week, the rally has been increasingly driven by a narrow group of mega-cap companies, which is reminiscent of the bubble in tech stocks at the turn of the century. With the economic rebound following the pandemic-induced slump now past its peak, some fund managers have warned that the next stage in the cycle is a correction, as central banks and governments wind down stimulus measures to tame surging inflation.\n\nFor JPMorgan strategists, however, the “extreme stock dispersion and record concentration within equities” is an indicator of an abundance of caution, not a looming selloff. Investors have been treating mega caps as safe-havens, or “pseudo-bonds,” the strategists wrote.\nIf anything, the drawdown in smaller companies offers investors attractive entry points for “reopening stocks”, such as travel and hospitality, as well as energy and e-commerce, as inflation normalizes and concerns over the Fed’s hawkishness abate, the strategists said.\nThe bullish outlook echoes the one of Goldman Sachs Group Inc. strategists, who also said earlier this month that the narrowing rally doesn’t point to an imminent major drawdown.\n“Rising concentration is not a reliable indicator for market peaks,” JPMorgan strategists said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607337845,"gmtCreate":1639487876269,"gmtModify":1639487876384,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Contradicting news. One article says there is effect and another no","listText":"Contradicting news. One article says there is effect and another no","text":"Contradicting news. One article says there is effect and another no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607337845","repostId":"1166095252","repostType":4,"repost":{"id":"1166095252","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639474104,"share":"https://www.laohu8.com/m/news/1166095252?lang=&edition=full","pubTime":"2021-12-14 17:28","market":"us","language":"en","title":"Pfizer slid in premarket trading as Oxford study found two vaccine doses wouldn’t protect from Omicron infection","url":"https://stock-news.laohu8.com/highlight/detail?id=1166095252","media":"Tiger Newspress","summary":"Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicro","content":"<p>Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicron infection.<img src=\"https://static.tigerbbs.com/012c95c2bcf1e6a1a1450958dd2f4e9e\" tg-width=\"766\" tg-height=\"558\" width=\"100%\" height=\"auto\">A new study from researchers at the University of Oxford has found two doses of either the Pfizer or AstraZeneca COVID-19 vaccine may not be enough to protect against infection from the Omicron variant. The data offers no indication of protection from severe disease, but shows two doses will not be enough to prevent Omicron infection in most people.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer slid in premarket trading as Oxford study found two vaccine doses wouldn’t protect from Omicron infection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer slid in premarket trading as Oxford study found two vaccine doses wouldn’t protect from Omicron infection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-14 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicron infection.<img src=\"https://static.tigerbbs.com/012c95c2bcf1e6a1a1450958dd2f4e9e\" tg-width=\"766\" tg-height=\"558\" width=\"100%\" height=\"auto\">A new study from researchers at the University of Oxford has found two doses of either the Pfizer or AstraZeneca COVID-19 vaccine may not be enough to protect against infection from the Omicron variant. The data offers no indication of protection from severe disease, but shows two doses will not be enough to prevent Omicron infection in most people.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166095252","content_text":"Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicron infection.A new study from researchers at the University of Oxford has found two doses of either the Pfizer or AstraZeneca COVID-19 vaccine may not be enough to protect against infection from the Omicron variant. The data offers no indication of protection from severe disease, but shows two doses will not be enough to prevent Omicron infection in most people.","news_type":1},"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605610328,"gmtCreate":1639151058755,"gmtModify":1639155628407,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/AMC 20220121 31.0 PUT\">$AMC 20220121 31.0 PUT$ &nbsp;</a>CEO dumping and telling apes he is just only planning for his future.","listText":"<a href=\"https://laohu8.com/OPT/AMC 20220121 31.0 PUT\">$AMC 20220121 31.0 PUT$ &nbsp;</a>CEO dumping and telling apes he is just only planning for his future.","text":"$AMC 20220121 31.0 PUT$ CEO dumping and telling apes he is just only planning for his future.","images":[{"img":"https://static.tigerbbs.com/f1ea3d77a8a159197f16133672d7d5da","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605610328","isVote":1,"tweetType":1,"viewCount":980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":608735438,"gmtCreate":1638788641270,"gmtModify":1638788641493,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes only a few companies are having insider buys. The overall market might still drop.","listText":"Yes only a few companies are having insider buys. The overall market might still drop.","text":"Yes only a few companies are having insider buys. The overall market might still drop.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608735438","repostId":"2188576930","repostType":2,"repost":{"id":"2188576930","pubTimestamp":1638774986,"share":"https://www.laohu8.com/m/news/2188576930?lang=&edition=full","pubTime":"2021-12-06 15:16","market":"us","language":"en","title":"Insider buying says a Santa Claus rally is on the way -- here are 10 stocks they favor","url":"https://stock-news.laohu8.com/highlight/detail?id=2188576930","media":"MarketWatch","summary":"Corporate insiders stepped up buying considerably when the stock market weakened. Hang on to your stock-market exposure and add more if you can.The twin fears spooking investors – the omicron COVID strain and inflation – are overdone. Stocks should proceed higher as more people figure this out, leading to a Santa Claus rally later this month.There are lots of stock bargains because there’s been so much damage, even if narrower indexes like the S&P 500 and the Dow Jones Industrial Average have hu","content":"<p>Corporate insiders stepped up buying considerably when the stock market weakened</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cb7144fa943d84b96ae88faa9be5533\" tg-width=\"700\" tg-height=\"487\" referrerpolicy=\"no-referrer\"><span>MarketWatch composite/Getty Images</span></p>\n<p>Hang on to your stock-market exposure and add more if you can.</p>\n<p>The twin fears spooking investors – the omicron COVID strain and inflation – are overdone. Stocks should proceed higher as more people figure this out, leading to a Santa Claus rally later this month.</p>\n<p>Corporate insiders confirm this view. They’ve stepped up buying considerably in the market weakness. What’s more they’re buying all the right groups – travel, retail, energy and materials, among others. These are the cyclical areas that’ll do the best as worries about growth recede, and insiders know it. I don’t see any hunkering down in defensive names like consumer staples.</p>\n<p>There are lots of stock bargains because there’s been so much damage, even if narrower indexes like the S&amp;P 500&nbsp;and the Dow Jones Industrial Average&nbsp;have hung tough, propped up by a few large names. The Russell 2000 small-cap index&nbsp;is down more than 10%, and most stocks in the more widely followed indexes like the S&amp;P 500 have also fallen more than 10% at some point recently.</p>\n<p>I’ll single out 10 names favored by insiders, including several I’ve recently suggested in my stock advisory letter Brush Up on Stocks (the link is in my bio, below). But first, a quick look at why insiders, like me, don’t seem to be too worried about the twin fears.</p>\n<p><b>Omicron</b></p>\n<p>The concern here is that this new variant is far more contagious and deadly than the delta variant.</p>\n<p>The first fear may be true. Case counts are rising sharply in South Africa, which suggests it is more contagious. As for lethality, though, omicron seems to be mild so far. There is still a lot to learn, but this is the message we consistently get from doctors and health authorities with lots of experience with COVID.</p>\n<p>“What we are seeing clinically in South Africa, and remember I’m at the epicenter of this where I’m practicing, is extremely mild for us,” says Angelique Coetzee, a doctor in South Africa who has three decades of experience. “These are mild cases. We haven’t admitted anyone. I’ve spoken to other colleagues of mine and they give the same picture.”</p>\n<p>Hospitalizations in South Africa “are ticking up but not incredibly fast,” agrees William Hanage, an associate professor of epidemiology at Harvard and co-director of its Center for Communicable Disease Dynamics. U.S. health authorities confirm omicron may not be especially lethal. Both the Centers for Disease Control and Prevention and the Minnesota Department of Health describe the first cases found in the U.S. so far as mild.</p>\n<p>if the omicron variant is mild, this wouldn’t be a surprise. Respiratory viruses naturally evolve to be <i>more contagious and less lethal</i>, notes Professor Karl Lauterbach, an epidemiologist in Germany. This makes sense from the point of view of a virus. A virus has a better chance if it spreads quickly and does not kill its host.</p>\n<p>On vaccine “escape” or evasion, former Food and Drug Administration chief Scott Gottlieb thinks the current vaccines will work against omicron by suppressing symptoms enough to lower hospitalizations. “There’s a high degree of confidence that efficacy is going to be preserved,” he says. “Will it be the same 95%? Perhaps not, but you will still have a meaningful amount of efficacy.”</p>\n<p>He notes the mRNA vaccine companies can tweak their vaccines to make them even better, in a matter of months. Vaccine companies like Pfizer&nbsp;confirm boosters will work, and that they’ll be able to customize them for the omicron variant. “In our view and reiterated by Pfizer, the current booster will likely be effective,” says Jefferies biotech analyst Michael Yee. “A new version for 2022 can be even better.”</p>\n<p><b>Inflation</b></p>\n<p>There’s are lots of reasons to think inflation fears are overblown. The worry here is that the Federal Reserve is “behind the curve” so it will have to hike rates aggressively, which might kill growth and the bull market. This isn’t going to happen. One sign is that commodity prices and shipping costs have been falling sharply. These are often the leading edge of inflation.</p>\n<p>Next, take a moment to drill down on the current inflation spike. To do so, consider the Atlanta Federal Reserve’s breakdown of the parts of the Core CPI Index into “flexible” categories (quick to change) and “sticky” categories (slow to change). Right now, the flexible components account for most of the headline inflation.</p>\n<p>These prices are up around 15% in the past year, compared to 3% gains for the “sticky” prices, points out economist Jim Paulsen, the market strategist at Leuthold Group. “While troublesome, the Core CPI Index’s overall rise is due almost entirely to prices that traditionally move around a lot, both up and down,” he says. This suggests the headline inflation rate can reverse and move down quickly from here.</p>\n<p>That’s what a lot of analysts and bond market investors think. Analysts expect inflation of less than 2% over the next two to 10 years, according to projections tracked by the Atlanta Fed. Meanwhile, the 10-year inflation rate projected by investors in the bond market stands at around 2.6%, notes Paulsen. Not terribly alarming.</p>\n<p>These projections make sense to me, because companies say their supply chain issues will be fixed by around the middle of next year. Shortages linked to supply chain issues have been a main contributor to price spikes.</p>\n<p>Finally, mobility tracking data from Alphabet,Apple,OpenTable and the Transportation Security Administration show that people in the U.S. have significantly curtailed how much they go out in public. On Nov. 30 and Dec. 1, TSA check-ins were 79%-81% of 2019 levels, compared to 85% to 90% in the prior 10 days, by my calculations. If this reduced mobility slows the economy a little, it will ease fears about inflation and the need for the Fed taking away the punch bowl too quickly.</p>\n<p><b>Insiders</b></p>\n<p>In a mini-replay of March-October of 2020 when the COVID crisis first raged, insiders have once again stepped up to buy market weakness caused by fresh COVID fears. True, insiders are not epidemiologists. But they are not dummies either. They have good networks of contacts and they see the tone of their businesses every day. Their buying is focused on all the right areas like cyclicals, retail, energy and industrials, not defensive names.</p>\n<p>Companies where insiders have been buying meaningful amounts over the past several days include outdoor and retail names Six Flags Entertainment,American Eagle Outfitters,Nordstrom&nbsp;and American Woodmark; travel names like Delta Air Lines&nbsp;and Playa Hotels &amp; Resorts ; energy names like Exxon Mobil&nbsp;and EOG Resources; and materials names like Cleveland-Cliffs&nbsp;and Orion Engineered Carbons.</p>\n<p><b>Ho, ho, ho!</b></p>\n<p>Their buying confirms work by seasonality and trading expert Larry Williams who tells me his work concludes we can expect a “Santa Claus” rally once again, later this month. We’ll see, but since the two main fears are false fears that will till take a little time to more fully recede, this makes sense to me.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insider buying says a Santa Claus rally is on the way -- here are 10 stocks they favor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsider buying says a Santa Claus rally is on the way -- here are 10 stocks they favor\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 15:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/insider-buying-says-a-santa-claus-rally-is-on-the-way-here-are-10-stocks-they-favor-11638541634?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corporate insiders stepped up buying considerably when the stock market weakened\nMarketWatch composite/Getty Images\nHang on to your stock-market exposure and add more if you can.\nThe twin fears ...</p>\n\n<a href=\"https://www.marketwatch.com/story/insider-buying-says-a-santa-claus-rally-is-on-the-way-here-are-10-stocks-they-favor-11638541634?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚","EOG":"依欧格资源","AMWD":"美国伍德马克","PLYA":"Playa Hotels & Resorts NV","SIX":"Six Flags Entertainment Corp","DAL":"达美航空","OEC":"Orion Engineered Carbons","JWN":"诺德斯特龙","AEO":"美鹰服饰","CLF":"克利夫兰克里夫"},"source_url":"https://www.marketwatch.com/story/insider-buying-says-a-santa-claus-rally-is-on-the-way-here-are-10-stocks-they-favor-11638541634?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188576930","content_text":"Corporate insiders stepped up buying considerably when the stock market weakened\nMarketWatch composite/Getty Images\nHang on to your stock-market exposure and add more if you can.\nThe twin fears spooking investors – the omicron COVID strain and inflation – are overdone. Stocks should proceed higher as more people figure this out, leading to a Santa Claus rally later this month.\nCorporate insiders confirm this view. They’ve stepped up buying considerably in the market weakness. What’s more they’re buying all the right groups – travel, retail, energy and materials, among others. These are the cyclical areas that’ll do the best as worries about growth recede, and insiders know it. I don’t see any hunkering down in defensive names like consumer staples.\nThere are lots of stock bargains because there’s been so much damage, even if narrower indexes like the S&P 500 and the Dow Jones Industrial Average have hung tough, propped up by a few large names. The Russell 2000 small-cap index is down more than 10%, and most stocks in the more widely followed indexes like the S&P 500 have also fallen more than 10% at some point recently.\nI’ll single out 10 names favored by insiders, including several I’ve recently suggested in my stock advisory letter Brush Up on Stocks (the link is in my bio, below). But first, a quick look at why insiders, like me, don’t seem to be too worried about the twin fears.\nOmicron\nThe concern here is that this new variant is far more contagious and deadly than the delta variant.\nThe first fear may be true. Case counts are rising sharply in South Africa, which suggests it is more contagious. As for lethality, though, omicron seems to be mild so far. There is still a lot to learn, but this is the message we consistently get from doctors and health authorities with lots of experience with COVID.\n“What we are seeing clinically in South Africa, and remember I’m at the epicenter of this where I’m practicing, is extremely mild for us,” says Angelique Coetzee, a doctor in South Africa who has three decades of experience. “These are mild cases. We haven’t admitted anyone. I’ve spoken to other colleagues of mine and they give the same picture.”\nHospitalizations in South Africa “are ticking up but not incredibly fast,” agrees William Hanage, an associate professor of epidemiology at Harvard and co-director of its Center for Communicable Disease Dynamics. U.S. health authorities confirm omicron may not be especially lethal. Both the Centers for Disease Control and Prevention and the Minnesota Department of Health describe the first cases found in the U.S. so far as mild.\nif the omicron variant is mild, this wouldn’t be a surprise. Respiratory viruses naturally evolve to be more contagious and less lethal, notes Professor Karl Lauterbach, an epidemiologist in Germany. This makes sense from the point of view of a virus. A virus has a better chance if it spreads quickly and does not kill its host.\nOn vaccine “escape” or evasion, former Food and Drug Administration chief Scott Gottlieb thinks the current vaccines will work against omicron by suppressing symptoms enough to lower hospitalizations. “There’s a high degree of confidence that efficacy is going to be preserved,” he says. “Will it be the same 95%? Perhaps not, but you will still have a meaningful amount of efficacy.”\nHe notes the mRNA vaccine companies can tweak their vaccines to make them even better, in a matter of months. Vaccine companies like Pfizer confirm boosters will work, and that they’ll be able to customize them for the omicron variant. “In our view and reiterated by Pfizer, the current booster will likely be effective,” says Jefferies biotech analyst Michael Yee. “A new version for 2022 can be even better.”\nInflation\nThere’s are lots of reasons to think inflation fears are overblown. The worry here is that the Federal Reserve is “behind the curve” so it will have to hike rates aggressively, which might kill growth and the bull market. This isn’t going to happen. One sign is that commodity prices and shipping costs have been falling sharply. These are often the leading edge of inflation.\nNext, take a moment to drill down on the current inflation spike. To do so, consider the Atlanta Federal Reserve’s breakdown of the parts of the Core CPI Index into “flexible” categories (quick to change) and “sticky” categories (slow to change). Right now, the flexible components account for most of the headline inflation.\nThese prices are up around 15% in the past year, compared to 3% gains for the “sticky” prices, points out economist Jim Paulsen, the market strategist at Leuthold Group. “While troublesome, the Core CPI Index’s overall rise is due almost entirely to prices that traditionally move around a lot, both up and down,” he says. This suggests the headline inflation rate can reverse and move down quickly from here.\nThat’s what a lot of analysts and bond market investors think. Analysts expect inflation of less than 2% over the next two to 10 years, according to projections tracked by the Atlanta Fed. Meanwhile, the 10-year inflation rate projected by investors in the bond market stands at around 2.6%, notes Paulsen. Not terribly alarming.\nThese projections make sense to me, because companies say their supply chain issues will be fixed by around the middle of next year. Shortages linked to supply chain issues have been a main contributor to price spikes.\nFinally, mobility tracking data from Alphabet,Apple,OpenTable and the Transportation Security Administration show that people in the U.S. have significantly curtailed how much they go out in public. On Nov. 30 and Dec. 1, TSA check-ins were 79%-81% of 2019 levels, compared to 85% to 90% in the prior 10 days, by my calculations. If this reduced mobility slows the economy a little, it will ease fears about inflation and the need for the Fed taking away the punch bowl too quickly.\nInsiders\nIn a mini-replay of March-October of 2020 when the COVID crisis first raged, insiders have once again stepped up to buy market weakness caused by fresh COVID fears. True, insiders are not epidemiologists. But they are not dummies either. They have good networks of contacts and they see the tone of their businesses every day. Their buying is focused on all the right areas like cyclicals, retail, energy and industrials, not defensive names.\nCompanies where insiders have been buying meaningful amounts over the past several days include outdoor and retail names Six Flags Entertainment,American Eagle Outfitters,Nordstrom and American Woodmark; travel names like Delta Air Lines and Playa Hotels & Resorts ; energy names like Exxon Mobil and EOG Resources; and materials names like Cleveland-Cliffs and Orion Engineered Carbons.\nHo, ho, ho!\nTheir buying confirms work by seasonality and trading expert Larry Williams who tells me his work concludes we can expect a “Santa Claus” rally once again, later this month. We’ll see, but since the two main fears are false fears that will till take a little time to more fully recede, this makes sense to me.","news_type":1},"isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603910513,"gmtCreate":1638350659261,"gmtModify":1638350659377,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20211217 55.0 PUT(SAVA)$</a>From last night's dip","listText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20211217 55.0 PUT(SAVA)$</a>From last night's dip","text":"$SAVA 20211217 55.0 PUT(SAVA)$From last night's dip","images":[{"img":"https://static.tigerbbs.com/203fa908c9ba26dc0ebbd78c62a1972c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/603910513","isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":874463424,"gmtCreate":1637812494081,"gmtModify":1637812498238,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Coming back alive again!","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Coming back alive again!","text":"$CHINA EAST EDU(00667)$Coming back alive again!","images":[{"img":"https://static.tigerbbs.com/a491745c70cf9170aaa26835d3b9aefb","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874463424","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":874268554,"gmtCreate":1637794018305,"gmtModify":1637794018305,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC 20220121 40.0 PUT(AMC)$</a>Earn a little from the drop","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC 20220121 40.0 PUT(AMC)$</a>Earn a little from the drop","text":"$AMC 20220121 40.0 PUT(AMC)$Earn a little from the drop","images":[{"img":"https://static.tigerbbs.com/909116bcb2fb67d3e9f7f824d843ee42","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874268554","isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":875163710,"gmtCreate":1637625726764,"gmtModify":1637625726764,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PROG\">$PROG 20220121 7.5 PUT(PROG)$</a>First round. Hoping to try the next round again.","listText":"<a href=\"https://laohu8.com/S/PROG\">$PROG 20220121 7.5 PUT(PROG)$</a>First round. Hoping to try the next round again.","text":"$PROG 20220121 7.5 PUT(PROG)$First round. Hoping to try the next round again.","images":[{"img":"https://static.tigerbbs.com/4a86d03c2ac2cbcd19048dd720c93471","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875163710","isVote":1,"tweetType":1,"viewCount":1116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":871996294,"gmtCreate":1637017510882,"gmtModify":1637017510882,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20220121 50.0 PUT(SAVA)$</a>Will exit for now. Probably will drop more or a crazy short squeeze might come.","listText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20220121 50.0 PUT(SAVA)$</a>Will exit for now. Probably will drop more or a crazy short squeeze might come.","text":"$SAVA 20220121 50.0 PUT(SAVA)$Will exit for now. Probably will drop more or a crazy short squeeze might come.","images":[{"img":"https://static.tigerbbs.com/4dd3a3b7d8ec22a6aa242267ace8910a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871996294","isVote":1,"tweetType":1,"viewCount":848,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844120548,"gmtCreate":1636412281228,"gmtModify":1636412281346,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Hope this isn't a dead cat bounce","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Hope this isn't a dead cat bounce","text":"$BioNTech SE(BNTX)$Hope this isn't a dead cat bounce","images":[{"img":"https://static.tigerbbs.com/4975e6843b31286b94dfcbd94a333537","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844120548","isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845051032,"gmtCreate":1636255911886,"gmtModify":1636255911999,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Part of the drop is due to Pfizer's announcement of their new covid 19 pill","listText":"Part of the drop is due to Pfizer's announcement of their new covid 19 pill","text":"Part of the drop is due to Pfizer's announcement of their new covid 19 pill","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/845051032","repostId":"2181742244","repostType":4,"repost":{"id":"2181742244","pubTimestamp":1636200360,"share":"https://www.laohu8.com/m/news/2181742244?lang=&edition=full","pubTime":"2021-11-06 20:06","market":"us","language":"en","title":"Why This Number in Moderna's Earnings Report Isn't as Bad as It Looks","url":"https://stock-news.laohu8.com/highlight/detail?id=2181742244","media":"Motley Fool","summary":"It's all about timing.","content":"<p>Vaccine giant <b>Moderna</b> (NASDAQ:MRNA) had been spoiling us. We'd gotten used to quarter after quarter of excellent news. And then, in the third-quarter earnings report this week, Moderna cut its 2021 vaccine revenue forecast. Moderna said it now predicts $15 billion to $18 billion in coronavirus vaccine revenue this year. That means revenue may be as much as $5 billion lower than expected.</p>\n<p>As a result, the shares sank 32% in two trading sessions. All of this sounds pretty grim. But, in fact, the situation isn't as bad as it looks. The $5 billion in revenue actually isn't lost. Let's take a closer look at why the market reaction was overdone -- and why the future still looks bright for this biotech company.</p>\n<h2>The earlier forecast</h2>\n<p>First, a little background. In Moderna's previous earnings report, the company forecast $20 billion in coronavirus vaccine sales for 2021. This is according to advance purchase agreements with various governments -- and the company's ability to deliver those particular orders this year.</p>\n<p>Fast forward to this week's earnings report. As mentioned above, Moderna predicted a lower number. But that isn't because Moderna lost orders or sales. The biotech still will bring in the full $20 billion. But part of it will come in a bit later. There are two reasons for this.</p>\n<p>First, Moderna is deferring the delivery of some vaccine doses to higher-income countries to early 2022. It's doing this so that it can prioritize doses to lower- and middle-income countries. And these countries pay lower prices. By delivering doses to the African Union and the COVAX initiative for equitable vaccine distribution instead of countries that pay more, Moderna will generate lower revenue in the coming weeks.</p>\n<p>Second, Moderna is shipping more doses internationally than it did earlier in the year. International shipping adds more time to the whole process of getting doses from factories to people's arms. Moderna expects to speed up the process once delivery to certain countries becomes routine. In the meantime, shipping abroad is slowing things down. And that means some deliveries meant for the fourth quarter instead will arrive in early 2022. As a result, Moderna will record sales from those orders in 2022 instead of 2021.</p>\n<h2>What does this mean for investors?</h2>\n<p>Right now, it's more important than ever to look at Moderna through a long-term lens. From quarter to quarter, vaccine deliveries -- and revenue -- may ebb and flow. And as we see here, this sort of movement has nothing to do with overall demand for the vaccine. In many cases, logistics can determine whether a delivery arrives in <a href=\"https://laohu8.com/S/AONE.U\">one</a> quarter or the next.</p>\n<p>Instead, we should look at the level of advance purchase orders for the coming year -- and how Moderna plans to evolve its coronavirus vaccine program in a post-pandemic world. Right now, Moderna has signed $17 billion in advance purchase agreements. These involve upfront payments so they are pretty secure. Moderna also has options for about $3 billion. That puts next year at about the same level as this year.</p>\n<p>Beyond that point, it's too early to predict exactly how much coronavirus vaccine or booster revenue will represent for Moderna. But it could remain significant. Experts say the coronavirus is here to stay. That means countries will need to stock up on vaccines or boosters for at least part of their populations. And Moderna is moving forward with exciting projects for a post-pandemic world. I'm thinking of its strain-specific booster candidates and a combined flu/coronavirus/allergies candidate.</p>\n<p>So, Moderna's change in this year's revenue guidance doesn't change my long-term outlook for the company. Instead, I see it as a reminder not to panic -- and to focus on the big picture over time.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why This Number in Moderna's Earnings Report Isn't as Bad as It Looks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy This Number in Moderna's Earnings Report Isn't as Bad as It Looks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 20:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/06/why-this-number-in-modernas-earnings-isnt-bad/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine giant Moderna (NASDAQ:MRNA) had been spoiling us. We'd gotten used to quarter after quarter of excellent news. And then, in the third-quarter earnings report this week, Moderna cut its 2021 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/06/why-this-number-in-modernas-earnings-isnt-bad/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/06/why-this-number-in-modernas-earnings-isnt-bad/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181742244","content_text":"Vaccine giant Moderna (NASDAQ:MRNA) had been spoiling us. We'd gotten used to quarter after quarter of excellent news. And then, in the third-quarter earnings report this week, Moderna cut its 2021 vaccine revenue forecast. Moderna said it now predicts $15 billion to $18 billion in coronavirus vaccine revenue this year. That means revenue may be as much as $5 billion lower than expected.\nAs a result, the shares sank 32% in two trading sessions. All of this sounds pretty grim. But, in fact, the situation isn't as bad as it looks. The $5 billion in revenue actually isn't lost. Let's take a closer look at why the market reaction was overdone -- and why the future still looks bright for this biotech company.\nThe earlier forecast\nFirst, a little background. In Moderna's previous earnings report, the company forecast $20 billion in coronavirus vaccine sales for 2021. This is according to advance purchase agreements with various governments -- and the company's ability to deliver those particular orders this year.\nFast forward to this week's earnings report. As mentioned above, Moderna predicted a lower number. But that isn't because Moderna lost orders or sales. The biotech still will bring in the full $20 billion. But part of it will come in a bit later. There are two reasons for this.\nFirst, Moderna is deferring the delivery of some vaccine doses to higher-income countries to early 2022. It's doing this so that it can prioritize doses to lower- and middle-income countries. And these countries pay lower prices. By delivering doses to the African Union and the COVAX initiative for equitable vaccine distribution instead of countries that pay more, Moderna will generate lower revenue in the coming weeks.\nSecond, Moderna is shipping more doses internationally than it did earlier in the year. International shipping adds more time to the whole process of getting doses from factories to people's arms. Moderna expects to speed up the process once delivery to certain countries becomes routine. In the meantime, shipping abroad is slowing things down. And that means some deliveries meant for the fourth quarter instead will arrive in early 2022. As a result, Moderna will record sales from those orders in 2022 instead of 2021.\nWhat does this mean for investors?\nRight now, it's more important than ever to look at Moderna through a long-term lens. From quarter to quarter, vaccine deliveries -- and revenue -- may ebb and flow. And as we see here, this sort of movement has nothing to do with overall demand for the vaccine. In many cases, logistics can determine whether a delivery arrives in one quarter or the next.\nInstead, we should look at the level of advance purchase orders for the coming year -- and how Moderna plans to evolve its coronavirus vaccine program in a post-pandemic world. Right now, Moderna has signed $17 billion in advance purchase agreements. These involve upfront payments so they are pretty secure. Moderna also has options for about $3 billion. That puts next year at about the same level as this year.\nBeyond that point, it's too early to predict exactly how much coronavirus vaccine or booster revenue will represent for Moderna. But it could remain significant. Experts say the coronavirus is here to stay. That means countries will need to stock up on vaccines or boosters for at least part of their populations. And Moderna is moving forward with exciting projects for a post-pandemic world. I'm thinking of its strain-specific booster candidates and a combined flu/coronavirus/allergies candidate.\nSo, Moderna's change in this year's revenue guidance doesn't change my long-term outlook for the company. Instead, I see it as a reminder not to panic -- and to focus on the big picture over time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841404284,"gmtCreate":1635930820035,"gmtModify":1635931302291,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>For two days the price make a full bounce![思考]&nbsp;","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>For two days the price make a full bounce![思考]&nbsp;","text":"$CHINA EAST EDU(00667)$For two days the price make a full bounce![思考]","images":[{"img":"https://static.tigerbbs.com/794798b338d076521ce105f8c83792ba","width":"1080","height":"3204"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841404284","isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":857618740,"gmtCreate":1635521459295,"gmtModify":1635521459295,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$TIGR 20220121 5.0 PUT(TIGR)$</a>Feel sad the stock of my favourite broker is going down.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$TIGR 20220121 5.0 PUT(TIGR)$</a>Feel sad the stock of my favourite broker is going down.","text":"$TIGR 20220121 5.0 PUT(TIGR)$Feel sad the stock of my favourite broker is going down.","images":[{"img":"https://static.tigerbbs.com/7b65122de2fcc9f8ed96ccd9226716a4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857618740","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":855947153,"gmtCreate":1635330272315,"gmtModify":1635330272315,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Good times don't last...never sell at $10. Now time to add instead.","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Good times don't last...never sell at $10. Now time to add instead.","text":"$CHINA EAST EDU(00667)$Good times don't last...never sell at $10. Now time to add instead.","images":[{"img":"https://static.tigerbbs.com/8d533849e2cca33067cb0879f7e61168","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855947153","isVote":1,"tweetType":1,"viewCount":328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":853301133,"gmtCreate":1634771579360,"gmtModify":1634771579443,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Jack had a good and long discussion and now time for his company to rise up to fair valuation. I don't think China will handicap the companies that will help it succeed.","listText":"Jack had a good and long discussion and now time for his company to rise up to fair valuation. I don't think China will handicap the companies that will help it succeed.","text":"Jack had a good and long discussion and now time for his company to rise up to fair valuation. I don't think China will handicap the companies that will help it succeed.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853301133","repostId":"2177436865","repostType":2,"isVote":1,"tweetType":1,"viewCount":152,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824971274,"gmtCreate":1634274616259,"gmtModify":1634274616259,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Should have stuck with my plan to add more at 7.60","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Should have stuck with my plan to add more at 7.60","text":"$CHINA EAST EDU(00667)$Should have stuck with my plan to add more at 7.60","images":[{"img":"https://static.tigerbbs.com/46c75ad0b784a4197516a224d7c37114","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824971274","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":825897851,"gmtCreate":1634215459015,"gmtModify":1634216214508,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a> The hammer is coming!Reuters news says: Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a> The hammer is coming!Reuters news says: Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website","text":"$Tiger Brokers(TIGR)$ The hammer is coming!Reuters news says: Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/825897851","isVote":1,"tweetType":1,"viewCount":715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821261140,"gmtCreate":1633748502632,"gmtModify":1633748502736,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Will the demand still be around by the time they start selling?","listText":"Will the demand still be around by the time they start selling?","text":"Will the demand still be around by the time they start selling?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821261140","repostId":"1198728824","repostType":4,"repost":{"id":"1198728824","pubTimestamp":1633699239,"share":"https://www.laohu8.com/m/news/1198728824?lang=&edition=full","pubTime":"2021-10-08 21:20","market":"us","language":"en","title":"Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=1198728824","media":"seekingalpha","summary":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a","content":"<p>Novavax is trading&nbsp;~1% higher&nbsp;in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19&nbsp;vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/4edc5f6f3230139f31f3c711942e1550\" tg-width=\"1185\" tg-height=\"577\" width=\"100%\" height=\"auto\"></p>\n<p>Per the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.</p>\n<p>Previously, Novavax(NASDAQ:NVAX)delayed the production and regulatory timeline for its protein-based vaccine&nbsp;candidate named NVX-CoV2373.</p>\n<p>However, it has generated promising results in a large Phase 3 clinical trial indicating 100% protection against moderate and severe COVID-19&nbsp;with ~90% overall efficacy.</p>\n<p>Novavax (NVAX)&nbsp;shares surged in September when the company announced the regulatory submission to the World Health Organization (WHO) seeking an emergency use listing (EUL)&nbsp;for the vaccine candidate.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the...</p>\n\n<a href=\"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1198728824","content_text":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.\nPreviously, Novavax(NASDAQ:NVAX)delayed the production and regulatory timeline for its protein-based vaccine candidate named NVX-CoV2373.\nHowever, it has generated promising results in a large Phase 3 clinical trial indicating 100% protection against moderate and severe COVID-19 with ~90% overall efficacy.\nNovavax (NVAX) shares surged in September when the company announced the regulatory submission to the World Health Organization (WHO) seeking an emergency use listing (EUL) for the vaccine candidate.","news_type":1},"isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821269842,"gmtCreate":1633748386018,"gmtModify":1633748386143,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Miss it at $30","listText":"Miss it at $30","text":"Miss it at $30","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821269842","repostId":"1100113443","repostType":4,"repost":{"id":"1100113443","pubTimestamp":1633699552,"share":"https://www.laohu8.com/m/news/1100113443?lang=&edition=full","pubTime":"2021-10-08 21:25","market":"us","language":"en","title":"ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1100113443","media":"seekingalpha","summary":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASD","content":"<p><b>Update</b>: Shares&nbsp;surge 80% in&nbsp;morning&nbsp;trading&nbsp;as trading resumed after FDA approval.</p>\n<p>ChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), in combination with standard therapy.</p>\n<p>The approval was supported by the results of the Phase III ADVOCATE trial. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks.</p>\n<p>TAVNEOS&nbsp;(avacopan) is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. The regulatory decision in Europe following the EMA review is expected by the end of 2021.</p>\n<p>ANCA-associated vasculitis is a systemic autoimmune disease, resulting in organ damage and failure, with the kidney as the major target, and is often fatal if not treated.</p>\n<p>CCXI shares&nbsp;tumbled 6%&nbsp;in premarket before they were halted for trading, which will resume at 7:30 am ET.</p>\n<p><img src=\"https://static.tigerbbs.com/6fa60267fef48df3f0a9f9c8658f1d60\" tg-width=\"1183\" tg-height=\"561\" width=\"100%\" height=\"auto\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective ...</p>\n\n<a href=\"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CCXI":"ChemoCentryx"},"source_url":"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1100113443","content_text":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), in combination with standard therapy.\nThe approval was supported by the results of the Phase III ADVOCATE trial. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks.\nTAVNEOS (avacopan) is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. The regulatory decision in Europe following the EMA review is expected by the end of 2021.\nANCA-associated vasculitis is a systemic autoimmune disease, resulting in organ damage and failure, with the kidney as the major target, and is often fatal if not treated.\nCCXI shares tumbled 6% in premarket before they were halted for trading, which will resume at 7:30 am ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":603910513,"gmtCreate":1638350659261,"gmtModify":1638350659377,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20211217 55.0 PUT(SAVA)$</a>From last night's dip","listText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20211217 55.0 PUT(SAVA)$</a>From last night's dip","text":"$SAVA 20211217 55.0 PUT(SAVA)$From last night's dip","images":[{"img":"https://static.tigerbbs.com/203fa908c9ba26dc0ebbd78c62a1972c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/603910513","isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845051032,"gmtCreate":1636255911886,"gmtModify":1636255911999,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Part of the drop is due to Pfizer's announcement of their new covid 19 pill","listText":"Part of the drop is due to Pfizer's announcement of their new covid 19 pill","text":"Part of the drop is due to Pfizer's announcement of their new covid 19 pill","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/845051032","repostId":"2181742244","repostType":4,"repost":{"id":"2181742244","pubTimestamp":1636200360,"share":"https://www.laohu8.com/m/news/2181742244?lang=&edition=full","pubTime":"2021-11-06 20:06","market":"us","language":"en","title":"Why This Number in Moderna's Earnings Report Isn't as Bad as It Looks","url":"https://stock-news.laohu8.com/highlight/detail?id=2181742244","media":"Motley Fool","summary":"It's all about timing.","content":"<p>Vaccine giant <b>Moderna</b> (NASDAQ:MRNA) had been spoiling us. We'd gotten used to quarter after quarter of excellent news. And then, in the third-quarter earnings report this week, Moderna cut its 2021 vaccine revenue forecast. Moderna said it now predicts $15 billion to $18 billion in coronavirus vaccine revenue this year. That means revenue may be as much as $5 billion lower than expected.</p>\n<p>As a result, the shares sank 32% in two trading sessions. All of this sounds pretty grim. But, in fact, the situation isn't as bad as it looks. The $5 billion in revenue actually isn't lost. Let's take a closer look at why the market reaction was overdone -- and why the future still looks bright for this biotech company.</p>\n<h2>The earlier forecast</h2>\n<p>First, a little background. In Moderna's previous earnings report, the company forecast $20 billion in coronavirus vaccine sales for 2021. This is according to advance purchase agreements with various governments -- and the company's ability to deliver those particular orders this year.</p>\n<p>Fast forward to this week's earnings report. As mentioned above, Moderna predicted a lower number. But that isn't because Moderna lost orders or sales. The biotech still will bring in the full $20 billion. But part of it will come in a bit later. There are two reasons for this.</p>\n<p>First, Moderna is deferring the delivery of some vaccine doses to higher-income countries to early 2022. It's doing this so that it can prioritize doses to lower- and middle-income countries. And these countries pay lower prices. By delivering doses to the African Union and the COVAX initiative for equitable vaccine distribution instead of countries that pay more, Moderna will generate lower revenue in the coming weeks.</p>\n<p>Second, Moderna is shipping more doses internationally than it did earlier in the year. International shipping adds more time to the whole process of getting doses from factories to people's arms. Moderna expects to speed up the process once delivery to certain countries becomes routine. In the meantime, shipping abroad is slowing things down. And that means some deliveries meant for the fourth quarter instead will arrive in early 2022. As a result, Moderna will record sales from those orders in 2022 instead of 2021.</p>\n<h2>What does this mean for investors?</h2>\n<p>Right now, it's more important than ever to look at Moderna through a long-term lens. From quarter to quarter, vaccine deliveries -- and revenue -- may ebb and flow. And as we see here, this sort of movement has nothing to do with overall demand for the vaccine. In many cases, logistics can determine whether a delivery arrives in <a href=\"https://laohu8.com/S/AONE.U\">one</a> quarter or the next.</p>\n<p>Instead, we should look at the level of advance purchase orders for the coming year -- and how Moderna plans to evolve its coronavirus vaccine program in a post-pandemic world. Right now, Moderna has signed $17 billion in advance purchase agreements. These involve upfront payments so they are pretty secure. Moderna also has options for about $3 billion. That puts next year at about the same level as this year.</p>\n<p>Beyond that point, it's too early to predict exactly how much coronavirus vaccine or booster revenue will represent for Moderna. But it could remain significant. Experts say the coronavirus is here to stay. That means countries will need to stock up on vaccines or boosters for at least part of their populations. And Moderna is moving forward with exciting projects for a post-pandemic world. I'm thinking of its strain-specific booster candidates and a combined flu/coronavirus/allergies candidate.</p>\n<p>So, Moderna's change in this year's revenue guidance doesn't change my long-term outlook for the company. Instead, I see it as a reminder not to panic -- and to focus on the big picture over time.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why This Number in Moderna's Earnings Report Isn't as Bad as It Looks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy This Number in Moderna's Earnings Report Isn't as Bad as It Looks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 20:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/06/why-this-number-in-modernas-earnings-isnt-bad/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine giant Moderna (NASDAQ:MRNA) had been spoiling us. We'd gotten used to quarter after quarter of excellent news. And then, in the third-quarter earnings report this week, Moderna cut its 2021 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/06/why-this-number-in-modernas-earnings-isnt-bad/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/06/why-this-number-in-modernas-earnings-isnt-bad/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181742244","content_text":"Vaccine giant Moderna (NASDAQ:MRNA) had been spoiling us. We'd gotten used to quarter after quarter of excellent news. And then, in the third-quarter earnings report this week, Moderna cut its 2021 vaccine revenue forecast. Moderna said it now predicts $15 billion to $18 billion in coronavirus vaccine revenue this year. That means revenue may be as much as $5 billion lower than expected.\nAs a result, the shares sank 32% in two trading sessions. All of this sounds pretty grim. But, in fact, the situation isn't as bad as it looks. The $5 billion in revenue actually isn't lost. Let's take a closer look at why the market reaction was overdone -- and why the future still looks bright for this biotech company.\nThe earlier forecast\nFirst, a little background. In Moderna's previous earnings report, the company forecast $20 billion in coronavirus vaccine sales for 2021. This is according to advance purchase agreements with various governments -- and the company's ability to deliver those particular orders this year.\nFast forward to this week's earnings report. As mentioned above, Moderna predicted a lower number. But that isn't because Moderna lost orders or sales. The biotech still will bring in the full $20 billion. But part of it will come in a bit later. There are two reasons for this.\nFirst, Moderna is deferring the delivery of some vaccine doses to higher-income countries to early 2022. It's doing this so that it can prioritize doses to lower- and middle-income countries. And these countries pay lower prices. By delivering doses to the African Union and the COVAX initiative for equitable vaccine distribution instead of countries that pay more, Moderna will generate lower revenue in the coming weeks.\nSecond, Moderna is shipping more doses internationally than it did earlier in the year. International shipping adds more time to the whole process of getting doses from factories to people's arms. Moderna expects to speed up the process once delivery to certain countries becomes routine. In the meantime, shipping abroad is slowing things down. And that means some deliveries meant for the fourth quarter instead will arrive in early 2022. As a result, Moderna will record sales from those orders in 2022 instead of 2021.\nWhat does this mean for investors?\nRight now, it's more important than ever to look at Moderna through a long-term lens. From quarter to quarter, vaccine deliveries -- and revenue -- may ebb and flow. And as we see here, this sort of movement has nothing to do with overall demand for the vaccine. In many cases, logistics can determine whether a delivery arrives in one quarter or the next.\nInstead, we should look at the level of advance purchase orders for the coming year -- and how Moderna plans to evolve its coronavirus vaccine program in a post-pandemic world. Right now, Moderna has signed $17 billion in advance purchase agreements. These involve upfront payments so they are pretty secure. Moderna also has options for about $3 billion. That puts next year at about the same level as this year.\nBeyond that point, it's too early to predict exactly how much coronavirus vaccine or booster revenue will represent for Moderna. But it could remain significant. Experts say the coronavirus is here to stay. That means countries will need to stock up on vaccines or boosters for at least part of their populations. And Moderna is moving forward with exciting projects for a post-pandemic world. I'm thinking of its strain-specific booster candidates and a combined flu/coronavirus/allergies candidate.\nSo, Moderna's change in this year's revenue guidance doesn't change my long-term outlook for the company. Instead, I see it as a reminder not to panic -- and to focus on the big picture over time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825897851,"gmtCreate":1634215459015,"gmtModify":1634216214508,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a> The hammer is coming!Reuters news says: Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a> The hammer is coming!Reuters news says: Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website","text":"$Tiger Brokers(TIGR)$ The hammer is coming!Reuters news says: Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/825897851","isVote":1,"tweetType":1,"viewCount":715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696978300,"gmtCreate":1640611889610,"gmtModify":1640611889703,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Tell they you this when they need you to line up on the buy queue","listText":"Tell they you this when they need you to line up on the buy queue","text":"Tell they you this when they need you to line up on the buy queue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696978300","repostId":"1169825066","repostType":2,"repost":{"id":"1169825066","pubTimestamp":1640606336,"share":"https://www.laohu8.com/m/news/1169825066?lang=&edition=full","pubTime":"2021-12-27 19:58","market":"us","language":"en","title":"JPMorgan Says Investors Too Bearish, Doesn’t See Stock Selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=1169825066","media":"Bloomberg","summary":"Strategists say market concentration doesn’t indicate peak\nU.S. rally may become broader in January,","content":"<ul>\n <li>Strategists say market concentration doesn’t indicate peak</li>\n <li>U.S. rally may become broader in January, according to note</li>\n</ul>\n<p>There’s no reason to fear that the rally that catapulted U.S. stocks to successive records this year will end anytime soon, according to JPMorgan Chase &amp; Co. strategists. In fact, more investors may soon join.</p>\n<p>“Conditions for a large selloff are not in place right now given already low investor positioning, record buybacks, limited systematic amplifiers, and positive January seasonals,” the strategists led by Dubravko Lakos-Bujas wrote in a note to clients. “Investor positioning is too bearish -- the market has taken the hawkish central bank and bearish omicron narratives too far.”</p>\n<p>While the S&amp;P 500 climbed to yet another record high last week, the rally has been increasingly driven by a narrow group of mega-cap companies, which is reminiscent of the bubble in tech stocks at the turn of the century. With the economic rebound following the pandemic-induced slump now past its peak, some fund managers have warned that the next stage in the cycle is a&nbsp;correction, as central banks and governments wind down stimulus measures to tame surging inflation.</p>\n<p><img src=\"https://static.tigerbbs.com/70927f00fd2b34d5345dd03f72195d1f\" tg-width=\"976\" tg-height=\"550\" width=\"100%\" height=\"auto\"></p>\n<p>For JPMorgan strategists, however, the “extreme stock dispersion and record concentration within equities” is an indicator of an abundance of caution, not a looming selloff. Investors have been treating mega caps as safe-havens, or “pseudo-bonds,” the strategists wrote.</p>\n<p>If anything, the drawdown in smaller companies offers investors attractive entry points for “reopening stocks”, such as travel and hospitality, as well as energy and e-commerce, as inflation normalizes and concerns over the Fed’s hawkishness abate, the strategists said.</p>\n<p>The bullish outlook echoes the one of Goldman Sachs Group Inc. strategists, who also said earlier this month that the narrowing rally doesn’t point to an imminent&nbsp;major drawdown.</p>\n<p>“Rising concentration is not a reliable indicator for market peaks,” JPMorgan strategists said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan Says Investors Too Bearish, Doesn’t See Stock Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan Says Investors Too Bearish, Doesn’t See Stock Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-27/jpmorgan-says-investors-too-bearish-doesn-t-see-stock-selloff?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Strategists say market concentration doesn’t indicate peak\nU.S. rally may become broader in January, according to note\n\nThere’s no reason to fear that the rally that catapulted U.S. stocks to ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-27/jpmorgan-says-investors-too-bearish-doesn-t-see-stock-selloff?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-27/jpmorgan-says-investors-too-bearish-doesn-t-see-stock-selloff?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169825066","content_text":"Strategists say market concentration doesn’t indicate peak\nU.S. rally may become broader in January, according to note\n\nThere’s no reason to fear that the rally that catapulted U.S. stocks to successive records this year will end anytime soon, according to JPMorgan Chase & Co. strategists. In fact, more investors may soon join.\n“Conditions for a large selloff are not in place right now given already low investor positioning, record buybacks, limited systematic amplifiers, and positive January seasonals,” the strategists led by Dubravko Lakos-Bujas wrote in a note to clients. “Investor positioning is too bearish -- the market has taken the hawkish central bank and bearish omicron narratives too far.”\nWhile the S&P 500 climbed to yet another record high last week, the rally has been increasingly driven by a narrow group of mega-cap companies, which is reminiscent of the bubble in tech stocks at the turn of the century. With the economic rebound following the pandemic-induced slump now past its peak, some fund managers have warned that the next stage in the cycle is a correction, as central banks and governments wind down stimulus measures to tame surging inflation.\n\nFor JPMorgan strategists, however, the “extreme stock dispersion and record concentration within equities” is an indicator of an abundance of caution, not a looming selloff. Investors have been treating mega caps as safe-havens, or “pseudo-bonds,” the strategists wrote.\nIf anything, the drawdown in smaller companies offers investors attractive entry points for “reopening stocks”, such as travel and hospitality, as well as energy and e-commerce, as inflation normalizes and concerns over the Fed’s hawkishness abate, the strategists said.\nThe bullish outlook echoes the one of Goldman Sachs Group Inc. strategists, who also said earlier this month that the narrowing rally doesn’t point to an imminent major drawdown.\n“Rising concentration is not a reliable indicator for market peaks,” JPMorgan strategists said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605610328,"gmtCreate":1639151058755,"gmtModify":1639155628407,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/AMC 20220121 31.0 PUT\">$AMC 20220121 31.0 PUT$ &nbsp;</a>CEO dumping and telling apes he is just only planning for his future.","listText":"<a href=\"https://laohu8.com/OPT/AMC 20220121 31.0 PUT\">$AMC 20220121 31.0 PUT$ &nbsp;</a>CEO dumping and telling apes he is just only planning for his future.","text":"$AMC 20220121 31.0 PUT$ CEO dumping and telling apes he is just only planning for his future.","images":[{"img":"https://static.tigerbbs.com/f1ea3d77a8a159197f16133672d7d5da","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605610328","isVote":1,"tweetType":1,"viewCount":980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":608735438,"gmtCreate":1638788641270,"gmtModify":1638788641493,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes only a few companies are having insider buys. The overall market might still drop.","listText":"Yes only a few companies are having insider buys. The overall market might still drop.","text":"Yes only a few companies are having insider buys. The overall market might still drop.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608735438","repostId":"2188576930","repostType":2,"repost":{"id":"2188576930","pubTimestamp":1638774986,"share":"https://www.laohu8.com/m/news/2188576930?lang=&edition=full","pubTime":"2021-12-06 15:16","market":"us","language":"en","title":"Insider buying says a Santa Claus rally is on the way -- here are 10 stocks they favor","url":"https://stock-news.laohu8.com/highlight/detail?id=2188576930","media":"MarketWatch","summary":"Corporate insiders stepped up buying considerably when the stock market weakened. Hang on to your stock-market exposure and add more if you can.The twin fears spooking investors – the omicron COVID strain and inflation – are overdone. Stocks should proceed higher as more people figure this out, leading to a Santa Claus rally later this month.There are lots of stock bargains because there’s been so much damage, even if narrower indexes like the S&P 500 and the Dow Jones Industrial Average have hu","content":"<p>Corporate insiders stepped up buying considerably when the stock market weakened</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cb7144fa943d84b96ae88faa9be5533\" tg-width=\"700\" tg-height=\"487\" referrerpolicy=\"no-referrer\"><span>MarketWatch composite/Getty Images</span></p>\n<p>Hang on to your stock-market exposure and add more if you can.</p>\n<p>The twin fears spooking investors – the omicron COVID strain and inflation – are overdone. Stocks should proceed higher as more people figure this out, leading to a Santa Claus rally later this month.</p>\n<p>Corporate insiders confirm this view. They’ve stepped up buying considerably in the market weakness. What’s more they’re buying all the right groups – travel, retail, energy and materials, among others. These are the cyclical areas that’ll do the best as worries about growth recede, and insiders know it. I don’t see any hunkering down in defensive names like consumer staples.</p>\n<p>There are lots of stock bargains because there’s been so much damage, even if narrower indexes like the S&amp;P 500&nbsp;and the Dow Jones Industrial Average&nbsp;have hung tough, propped up by a few large names. The Russell 2000 small-cap index&nbsp;is down more than 10%, and most stocks in the more widely followed indexes like the S&amp;P 500 have also fallen more than 10% at some point recently.</p>\n<p>I’ll single out 10 names favored by insiders, including several I’ve recently suggested in my stock advisory letter Brush Up on Stocks (the link is in my bio, below). But first, a quick look at why insiders, like me, don’t seem to be too worried about the twin fears.</p>\n<p><b>Omicron</b></p>\n<p>The concern here is that this new variant is far more contagious and deadly than the delta variant.</p>\n<p>The first fear may be true. Case counts are rising sharply in South Africa, which suggests it is more contagious. As for lethality, though, omicron seems to be mild so far. There is still a lot to learn, but this is the message we consistently get from doctors and health authorities with lots of experience with COVID.</p>\n<p>“What we are seeing clinically in South Africa, and remember I’m at the epicenter of this where I’m practicing, is extremely mild for us,” says Angelique Coetzee, a doctor in South Africa who has three decades of experience. “These are mild cases. We haven’t admitted anyone. I’ve spoken to other colleagues of mine and they give the same picture.”</p>\n<p>Hospitalizations in South Africa “are ticking up but not incredibly fast,” agrees William Hanage, an associate professor of epidemiology at Harvard and co-director of its Center for Communicable Disease Dynamics. U.S. health authorities confirm omicron may not be especially lethal. Both the Centers for Disease Control and Prevention and the Minnesota Department of Health describe the first cases found in the U.S. so far as mild.</p>\n<p>if the omicron variant is mild, this wouldn’t be a surprise. Respiratory viruses naturally evolve to be <i>more contagious and less lethal</i>, notes Professor Karl Lauterbach, an epidemiologist in Germany. This makes sense from the point of view of a virus. A virus has a better chance if it spreads quickly and does not kill its host.</p>\n<p>On vaccine “escape” or evasion, former Food and Drug Administration chief Scott Gottlieb thinks the current vaccines will work against omicron by suppressing symptoms enough to lower hospitalizations. “There’s a high degree of confidence that efficacy is going to be preserved,” he says. “Will it be the same 95%? Perhaps not, but you will still have a meaningful amount of efficacy.”</p>\n<p>He notes the mRNA vaccine companies can tweak their vaccines to make them even better, in a matter of months. Vaccine companies like Pfizer&nbsp;confirm boosters will work, and that they’ll be able to customize them for the omicron variant. “In our view and reiterated by Pfizer, the current booster will likely be effective,” says Jefferies biotech analyst Michael Yee. “A new version for 2022 can be even better.”</p>\n<p><b>Inflation</b></p>\n<p>There’s are lots of reasons to think inflation fears are overblown. The worry here is that the Federal Reserve is “behind the curve” so it will have to hike rates aggressively, which might kill growth and the bull market. This isn’t going to happen. One sign is that commodity prices and shipping costs have been falling sharply. These are often the leading edge of inflation.</p>\n<p>Next, take a moment to drill down on the current inflation spike. To do so, consider the Atlanta Federal Reserve’s breakdown of the parts of the Core CPI Index into “flexible” categories (quick to change) and “sticky” categories (slow to change). Right now, the flexible components account for most of the headline inflation.</p>\n<p>These prices are up around 15% in the past year, compared to 3% gains for the “sticky” prices, points out economist Jim Paulsen, the market strategist at Leuthold Group. “While troublesome, the Core CPI Index’s overall rise is due almost entirely to prices that traditionally move around a lot, both up and down,” he says. This suggests the headline inflation rate can reverse and move down quickly from here.</p>\n<p>That’s what a lot of analysts and bond market investors think. Analysts expect inflation of less than 2% over the next two to 10 years, according to projections tracked by the Atlanta Fed. Meanwhile, the 10-year inflation rate projected by investors in the bond market stands at around 2.6%, notes Paulsen. Not terribly alarming.</p>\n<p>These projections make sense to me, because companies say their supply chain issues will be fixed by around the middle of next year. Shortages linked to supply chain issues have been a main contributor to price spikes.</p>\n<p>Finally, mobility tracking data from Alphabet,Apple,OpenTable and the Transportation Security Administration show that people in the U.S. have significantly curtailed how much they go out in public. On Nov. 30 and Dec. 1, TSA check-ins were 79%-81% of 2019 levels, compared to 85% to 90% in the prior 10 days, by my calculations. If this reduced mobility slows the economy a little, it will ease fears about inflation and the need for the Fed taking away the punch bowl too quickly.</p>\n<p><b>Insiders</b></p>\n<p>In a mini-replay of March-October of 2020 when the COVID crisis first raged, insiders have once again stepped up to buy market weakness caused by fresh COVID fears. True, insiders are not epidemiologists. But they are not dummies either. They have good networks of contacts and they see the tone of their businesses every day. Their buying is focused on all the right areas like cyclicals, retail, energy and industrials, not defensive names.</p>\n<p>Companies where insiders have been buying meaningful amounts over the past several days include outdoor and retail names Six Flags Entertainment,American Eagle Outfitters,Nordstrom&nbsp;and American Woodmark; travel names like Delta Air Lines&nbsp;and Playa Hotels &amp; Resorts ; energy names like Exxon Mobil&nbsp;and EOG Resources; and materials names like Cleveland-Cliffs&nbsp;and Orion Engineered Carbons.</p>\n<p><b>Ho, ho, ho!</b></p>\n<p>Their buying confirms work by seasonality and trading expert Larry Williams who tells me his work concludes we can expect a “Santa Claus” rally once again, later this month. We’ll see, but since the two main fears are false fears that will till take a little time to more fully recede, this makes sense to me.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insider buying says a Santa Claus rally is on the way -- here are 10 stocks they favor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsider buying says a Santa Claus rally is on the way -- here are 10 stocks they favor\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 15:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/insider-buying-says-a-santa-claus-rally-is-on-the-way-here-are-10-stocks-they-favor-11638541634?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corporate insiders stepped up buying considerably when the stock market weakened\nMarketWatch composite/Getty Images\nHang on to your stock-market exposure and add more if you can.\nThe twin fears ...</p>\n\n<a href=\"https://www.marketwatch.com/story/insider-buying-says-a-santa-claus-rally-is-on-the-way-here-are-10-stocks-they-favor-11638541634?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚","EOG":"依欧格资源","AMWD":"美国伍德马克","PLYA":"Playa Hotels & Resorts NV","SIX":"Six Flags Entertainment Corp","DAL":"达美航空","OEC":"Orion Engineered Carbons","JWN":"诺德斯特龙","AEO":"美鹰服饰","CLF":"克利夫兰克里夫"},"source_url":"https://www.marketwatch.com/story/insider-buying-says-a-santa-claus-rally-is-on-the-way-here-are-10-stocks-they-favor-11638541634?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188576930","content_text":"Corporate insiders stepped up buying considerably when the stock market weakened\nMarketWatch composite/Getty Images\nHang on to your stock-market exposure and add more if you can.\nThe twin fears spooking investors – the omicron COVID strain and inflation – are overdone. Stocks should proceed higher as more people figure this out, leading to a Santa Claus rally later this month.\nCorporate insiders confirm this view. They’ve stepped up buying considerably in the market weakness. What’s more they’re buying all the right groups – travel, retail, energy and materials, among others. These are the cyclical areas that’ll do the best as worries about growth recede, and insiders know it. I don’t see any hunkering down in defensive names like consumer staples.\nThere are lots of stock bargains because there’s been so much damage, even if narrower indexes like the S&P 500 and the Dow Jones Industrial Average have hung tough, propped up by a few large names. The Russell 2000 small-cap index is down more than 10%, and most stocks in the more widely followed indexes like the S&P 500 have also fallen more than 10% at some point recently.\nI’ll single out 10 names favored by insiders, including several I’ve recently suggested in my stock advisory letter Brush Up on Stocks (the link is in my bio, below). But first, a quick look at why insiders, like me, don’t seem to be too worried about the twin fears.\nOmicron\nThe concern here is that this new variant is far more contagious and deadly than the delta variant.\nThe first fear may be true. Case counts are rising sharply in South Africa, which suggests it is more contagious. As for lethality, though, omicron seems to be mild so far. There is still a lot to learn, but this is the message we consistently get from doctors and health authorities with lots of experience with COVID.\n“What we are seeing clinically in South Africa, and remember I’m at the epicenter of this where I’m practicing, is extremely mild for us,” says Angelique Coetzee, a doctor in South Africa who has three decades of experience. “These are mild cases. We haven’t admitted anyone. I’ve spoken to other colleagues of mine and they give the same picture.”\nHospitalizations in South Africa “are ticking up but not incredibly fast,” agrees William Hanage, an associate professor of epidemiology at Harvard and co-director of its Center for Communicable Disease Dynamics. U.S. health authorities confirm omicron may not be especially lethal. Both the Centers for Disease Control and Prevention and the Minnesota Department of Health describe the first cases found in the U.S. so far as mild.\nif the omicron variant is mild, this wouldn’t be a surprise. Respiratory viruses naturally evolve to be more contagious and less lethal, notes Professor Karl Lauterbach, an epidemiologist in Germany. This makes sense from the point of view of a virus. A virus has a better chance if it spreads quickly and does not kill its host.\nOn vaccine “escape” or evasion, former Food and Drug Administration chief Scott Gottlieb thinks the current vaccines will work against omicron by suppressing symptoms enough to lower hospitalizations. “There’s a high degree of confidence that efficacy is going to be preserved,” he says. “Will it be the same 95%? Perhaps not, but you will still have a meaningful amount of efficacy.”\nHe notes the mRNA vaccine companies can tweak their vaccines to make them even better, in a matter of months. Vaccine companies like Pfizer confirm boosters will work, and that they’ll be able to customize them for the omicron variant. “In our view and reiterated by Pfizer, the current booster will likely be effective,” says Jefferies biotech analyst Michael Yee. “A new version for 2022 can be even better.”\nInflation\nThere’s are lots of reasons to think inflation fears are overblown. The worry here is that the Federal Reserve is “behind the curve” so it will have to hike rates aggressively, which might kill growth and the bull market. This isn’t going to happen. One sign is that commodity prices and shipping costs have been falling sharply. These are often the leading edge of inflation.\nNext, take a moment to drill down on the current inflation spike. To do so, consider the Atlanta Federal Reserve’s breakdown of the parts of the Core CPI Index into “flexible” categories (quick to change) and “sticky” categories (slow to change). Right now, the flexible components account for most of the headline inflation.\nThese prices are up around 15% in the past year, compared to 3% gains for the “sticky” prices, points out economist Jim Paulsen, the market strategist at Leuthold Group. “While troublesome, the Core CPI Index’s overall rise is due almost entirely to prices that traditionally move around a lot, both up and down,” he says. This suggests the headline inflation rate can reverse and move down quickly from here.\nThat’s what a lot of analysts and bond market investors think. Analysts expect inflation of less than 2% over the next two to 10 years, according to projections tracked by the Atlanta Fed. Meanwhile, the 10-year inflation rate projected by investors in the bond market stands at around 2.6%, notes Paulsen. Not terribly alarming.\nThese projections make sense to me, because companies say their supply chain issues will be fixed by around the middle of next year. Shortages linked to supply chain issues have been a main contributor to price spikes.\nFinally, mobility tracking data from Alphabet,Apple,OpenTable and the Transportation Security Administration show that people in the U.S. have significantly curtailed how much they go out in public. On Nov. 30 and Dec. 1, TSA check-ins were 79%-81% of 2019 levels, compared to 85% to 90% in the prior 10 days, by my calculations. If this reduced mobility slows the economy a little, it will ease fears about inflation and the need for the Fed taking away the punch bowl too quickly.\nInsiders\nIn a mini-replay of March-October of 2020 when the COVID crisis first raged, insiders have once again stepped up to buy market weakness caused by fresh COVID fears. True, insiders are not epidemiologists. But they are not dummies either. They have good networks of contacts and they see the tone of their businesses every day. Their buying is focused on all the right areas like cyclicals, retail, energy and industrials, not defensive names.\nCompanies where insiders have been buying meaningful amounts over the past several days include outdoor and retail names Six Flags Entertainment,American Eagle Outfitters,Nordstrom and American Woodmark; travel names like Delta Air Lines and Playa Hotels & Resorts ; energy names like Exxon Mobil and EOG Resources; and materials names like Cleveland-Cliffs and Orion Engineered Carbons.\nHo, ho, ho!\nTheir buying confirms work by seasonality and trading expert Larry Williams who tells me his work concludes we can expect a “Santa Claus” rally once again, later this month. We’ll see, but since the two main fears are false fears that will till take a little time to more fully recede, this makes sense to me.","news_type":1},"isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874268554,"gmtCreate":1637794018305,"gmtModify":1637794018305,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC 20220121 40.0 PUT(AMC)$</a>Earn a little from the drop","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC 20220121 40.0 PUT(AMC)$</a>Earn a little from the drop","text":"$AMC 20220121 40.0 PUT(AMC)$Earn a little from the drop","images":[{"img":"https://static.tigerbbs.com/909116bcb2fb67d3e9f7f824d843ee42","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874268554","isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":875163710,"gmtCreate":1637625726764,"gmtModify":1637625726764,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PROG\">$PROG 20220121 7.5 PUT(PROG)$</a>First round. Hoping to try the next round again.","listText":"<a href=\"https://laohu8.com/S/PROG\">$PROG 20220121 7.5 PUT(PROG)$</a>First round. Hoping to try the next round again.","text":"$PROG 20220121 7.5 PUT(PROG)$First round. Hoping to try the next round again.","images":[{"img":"https://static.tigerbbs.com/4a86d03c2ac2cbcd19048dd720c93471","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875163710","isVote":1,"tweetType":1,"viewCount":1116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":871996294,"gmtCreate":1637017510882,"gmtModify":1637017510882,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20220121 50.0 PUT(SAVA)$</a>Will exit for now. Probably will drop more or a crazy short squeeze might come.","listText":"<a href=\"https://laohu8.com/S/SAVA\">$SAVA 20220121 50.0 PUT(SAVA)$</a>Will exit for now. Probably will drop more or a crazy short squeeze might come.","text":"$SAVA 20220121 50.0 PUT(SAVA)$Will exit for now. Probably will drop more or a crazy short squeeze might come.","images":[{"img":"https://static.tigerbbs.com/4dd3a3b7d8ec22a6aa242267ace8910a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871996294","isVote":1,"tweetType":1,"viewCount":848,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":857618740,"gmtCreate":1635521459295,"gmtModify":1635521459295,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$TIGR 20220121 5.0 PUT(TIGR)$</a>Feel sad the stock of my favourite broker is going down.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$TIGR 20220121 5.0 PUT(TIGR)$</a>Feel sad the stock of my favourite broker is going down.","text":"$TIGR 20220121 5.0 PUT(TIGR)$Feel sad the stock of my favourite broker is going down.","images":[{"img":"https://static.tigerbbs.com/7b65122de2fcc9f8ed96ccd9226716a4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857618740","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":855947153,"gmtCreate":1635330272315,"gmtModify":1635330272315,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Good times don't last...never sell at $10. Now time to add instead.","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Good times don't last...never sell at $10. Now time to add instead.","text":"$CHINA EAST EDU(00667)$Good times don't last...never sell at $10. Now time to add instead.","images":[{"img":"https://static.tigerbbs.com/8d533849e2cca33067cb0879f7e61168","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855947153","isVote":1,"tweetType":1,"viewCount":328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":824971274,"gmtCreate":1634274616259,"gmtModify":1634274616259,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Should have stuck with my plan to add more at 7.60","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Should have stuck with my plan to add more at 7.60","text":"$CHINA EAST EDU(00667)$Should have stuck with my plan to add more at 7.60","images":[{"img":"https://static.tigerbbs.com/46c75ad0b784a4197516a224d7c37114","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824971274","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":607337845,"gmtCreate":1639487876269,"gmtModify":1639487876384,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Contradicting news. One article says there is effect and another no","listText":"Contradicting news. One article says there is effect and another no","text":"Contradicting news. One article says there is effect and another no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607337845","repostId":"1166095252","repostType":4,"repost":{"id":"1166095252","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639474104,"share":"https://www.laohu8.com/m/news/1166095252?lang=&edition=full","pubTime":"2021-12-14 17:28","market":"us","language":"en","title":"Pfizer slid in premarket trading as Oxford study found two vaccine doses wouldn’t protect from Omicron infection","url":"https://stock-news.laohu8.com/highlight/detail?id=1166095252","media":"Tiger Newspress","summary":"Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicro","content":"<p>Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicron infection.<img src=\"https://static.tigerbbs.com/012c95c2bcf1e6a1a1450958dd2f4e9e\" tg-width=\"766\" tg-height=\"558\" width=\"100%\" height=\"auto\">A new study from researchers at the University of Oxford has found two doses of either the Pfizer or AstraZeneca COVID-19 vaccine may not be enough to protect against infection from the Omicron variant. The data offers no indication of protection from severe disease, but shows two doses will not be enough to prevent Omicron infection in most people.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer slid in premarket trading as Oxford study found two vaccine doses wouldn’t protect from Omicron infection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer slid in premarket trading as Oxford study found two vaccine doses wouldn’t protect from Omicron infection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-14 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicron infection.<img src=\"https://static.tigerbbs.com/012c95c2bcf1e6a1a1450958dd2f4e9e\" tg-width=\"766\" tg-height=\"558\" width=\"100%\" height=\"auto\">A new study from researchers at the University of Oxford has found two doses of either the Pfizer or AstraZeneca COVID-19 vaccine may not be enough to protect against infection from the Omicron variant. The data offers no indication of protection from severe disease, but shows two doses will not be enough to prevent Omicron infection in most people.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166095252","content_text":"Pfizer slid in premarket trading asOxford study found two vaccine doses wouldn’t protect from Omicron infection.A new study from researchers at the University of Oxford has found two doses of either the Pfizer or AstraZeneca COVID-19 vaccine may not be enough to protect against infection from the Omicron variant. The data offers no indication of protection from severe disease, but shows two doses will not be enough to prevent Omicron infection in most people.","news_type":1},"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874463424,"gmtCreate":1637812494081,"gmtModify":1637812498238,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Coming back alive again!","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>Coming back alive again!","text":"$CHINA EAST EDU(00667)$Coming back alive again!","images":[{"img":"https://static.tigerbbs.com/a491745c70cf9170aaa26835d3b9aefb","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874463424","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844120548,"gmtCreate":1636412281228,"gmtModify":1636412281346,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Hope this isn't a dead cat bounce","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Hope this isn't a dead cat bounce","text":"$BioNTech SE(BNTX)$Hope this isn't a dead cat bounce","images":[{"img":"https://static.tigerbbs.com/4975e6843b31286b94dfcbd94a333537","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844120548","isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":853301133,"gmtCreate":1634771579360,"gmtModify":1634771579443,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Jack had a good and long discussion and now time for his company to rise up to fair valuation. I don't think China will handicap the companies that will help it succeed.","listText":"Jack had a good and long discussion and now time for his company to rise up to fair valuation. I don't think China will handicap the companies that will help it succeed.","text":"Jack had a good and long discussion and now time for his company to rise up to fair valuation. I don't think China will handicap the companies that will help it succeed.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853301133","repostId":"2177436865","repostType":2,"isVote":1,"tweetType":1,"viewCount":152,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821261140,"gmtCreate":1633748502632,"gmtModify":1633748502736,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Will the demand still be around by the time they start selling?","listText":"Will the demand still be around by the time they start selling?","text":"Will the demand still be around by the time they start selling?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821261140","repostId":"1198728824","repostType":4,"repost":{"id":"1198728824","pubTimestamp":1633699239,"share":"https://www.laohu8.com/m/news/1198728824?lang=&edition=full","pubTime":"2021-10-08 21:20","market":"us","language":"en","title":"Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=1198728824","media":"seekingalpha","summary":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a","content":"<p>Novavax is trading&nbsp;~1% higher&nbsp;in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19&nbsp;vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/4edc5f6f3230139f31f3c711942e1550\" tg-width=\"1185\" tg-height=\"577\" width=\"100%\" height=\"auto\"></p>\n<p>Per the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.</p>\n<p>Previously, Novavax(NASDAQ:NVAX)delayed the production and regulatory timeline for its protein-based vaccine&nbsp;candidate named NVX-CoV2373.</p>\n<p>However, it has generated promising results in a large Phase 3 clinical trial indicating 100% protection against moderate and severe COVID-19&nbsp;with ~90% overall efficacy.</p>\n<p>Novavax (NVAX)&nbsp;shares surged in September when the company announced the regulatory submission to the World Health Organization (WHO) seeking an emergency use listing (EUL)&nbsp;for the vaccine candidate.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the...</p>\n\n<a href=\"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1198728824","content_text":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.\nPreviously, Novavax(NASDAQ:NVAX)delayed the production and regulatory timeline for its protein-based vaccine candidate named NVX-CoV2373.\nHowever, it has generated promising results in a large Phase 3 clinical trial indicating 100% protection against moderate and severe COVID-19 with ~90% overall efficacy.\nNovavax (NVAX) shares surged in September when the company announced the regulatory submission to the World Health Organization (WHO) seeking an emergency use listing (EUL) for the vaccine candidate.","news_type":1},"isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821269842,"gmtCreate":1633748386018,"gmtModify":1633748386143,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Miss it at $30","listText":"Miss it at $30","text":"Miss it at $30","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821269842","repostId":"1100113443","repostType":4,"repost":{"id":"1100113443","pubTimestamp":1633699552,"share":"https://www.laohu8.com/m/news/1100113443?lang=&edition=full","pubTime":"2021-10-08 21:25","market":"us","language":"en","title":"ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1100113443","media":"seekingalpha","summary":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASD","content":"<p><b>Update</b>: Shares&nbsp;surge 80% in&nbsp;morning&nbsp;trading&nbsp;as trading resumed after FDA approval.</p>\n<p>ChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), in combination with standard therapy.</p>\n<p>The approval was supported by the results of the Phase III ADVOCATE trial. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks.</p>\n<p>TAVNEOS&nbsp;(avacopan) is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. The regulatory decision in Europe following the EMA review is expected by the end of 2021.</p>\n<p>ANCA-associated vasculitis is a systemic autoimmune disease, resulting in organ damage and failure, with the kidney as the major target, and is often fatal if not treated.</p>\n<p>CCXI shares&nbsp;tumbled 6%&nbsp;in premarket before they were halted for trading, which will resume at 7:30 am ET.</p>\n<p><img src=\"https://static.tigerbbs.com/6fa60267fef48df3f0a9f9c8658f1d60\" tg-width=\"1183\" tg-height=\"561\" width=\"100%\" height=\"auto\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective ...</p>\n\n<a href=\"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CCXI":"ChemoCentryx"},"source_url":"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1100113443","content_text":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), in combination with standard therapy.\nThe approval was supported by the results of the Phase III ADVOCATE trial. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks.\nTAVNEOS (avacopan) is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. The regulatory decision in Europe following the EMA review is expected by the end of 2021.\nANCA-associated vasculitis is a systemic autoimmune disease, resulting in organ damage and failure, with the kidney as the major target, and is often fatal if not treated.\nCCXI shares tumbled 6% in premarket before they were halted for trading, which will resume at 7:30 am ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692114821,"gmtCreate":1640874175584,"gmtModify":1640874175668,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Failed stock and company. Can't even do a buy back.","listText":"Failed stock and company. Can't even do a buy back.","text":"Failed stock and company. Can't even do a buy back.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692114821","repostId":"1183919949","repostType":4,"repost":{"id":"1183919949","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640854650,"share":"https://www.laohu8.com/m/news/1183919949?lang=&edition=full","pubTime":"2021-12-30 16:57","market":"us","language":"en","title":"DiDi Stock Dropped 2% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1183919949","media":"Tiger Newspress","summary":"DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareho","content":"<html><head></head><body><p>DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareholders of RMB 30.6B (US$4.7B) in its Q3 earning report.</p><p><img src=\"https://static.tigerbbs.com/ce293b188578845e5e6bf0ebc79dc772\" tg-width=\"1129\" tg-height=\"716\" referrerpolicy=\"no-referrer\"/>DiDi Q3 adjusted EBITA was a loss of RMB 7.5B (US$1.2B), after posting Q2 adjusted EBITDA loss of RMB 2.3B.</p><p>Core platform transactions for Q3 were 2.86B vs. 3.00B in Q2, with transactions for its China Mobility segment at 2.36B vs. 2.57B in the prior quarter. Transactions for the International segment were 499M.</p><p>Q3 core platform gross transaction value reached RMB 68.7B (US$10.7B), down from $MB73.3B in Q2; GTV from the China Mobility segment of RMB 58.4B (US$9.1B) slipped from RMB 64.6B in Q2.</p><p>Q3 total revenue of RMB 42.7B (US$6.6B), dropped from RMB 48.2B in Q2, with revenue from China Mobility at RMB 39.0B (US$6.1B) vs. RMB 44.8B in Q2 2021.</p><p>The company also said it will schedule a shareholders meeting for a vote on choosing another internationally recognized stock exchange for listing shares that will convert from its ADSs, which now trade on the NYSE. On Dec. 3, DiDi&#39;s (DIDI) board said it would delist its ADSs from the NYSE.</p><p>The company also announced changes to its board.DiDi (DIDI) ADSsrise 1.1% in after-hours trading in New York.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiDi Stock Dropped 2% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiDi Stock Dropped 2% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-30 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareholders of RMB 30.6B (US$4.7B) in its Q3 earning report.</p><p><img src=\"https://static.tigerbbs.com/ce293b188578845e5e6bf0ebc79dc772\" tg-width=\"1129\" tg-height=\"716\" referrerpolicy=\"no-referrer\"/>DiDi Q3 adjusted EBITA was a loss of RMB 7.5B (US$1.2B), after posting Q2 adjusted EBITDA loss of RMB 2.3B.</p><p>Core platform transactions for Q3 were 2.86B vs. 3.00B in Q2, with transactions for its China Mobility segment at 2.36B vs. 2.57B in the prior quarter. Transactions for the International segment were 499M.</p><p>Q3 core platform gross transaction value reached RMB 68.7B (US$10.7B), down from $MB73.3B in Q2; GTV from the China Mobility segment of RMB 58.4B (US$9.1B) slipped from RMB 64.6B in Q2.</p><p>Q3 total revenue of RMB 42.7B (US$6.6B), dropped from RMB 48.2B in Q2, with revenue from China Mobility at RMB 39.0B (US$6.1B) vs. RMB 44.8B in Q2 2021.</p><p>The company also said it will schedule a shareholders meeting for a vote on choosing another internationally recognized stock exchange for listing shares that will convert from its ADSs, which now trade on the NYSE. On Dec. 3, DiDi&#39;s (DIDI) board said it would delist its ADSs from the NYSE.</p><p>The company also announced changes to its board.DiDi (DIDI) ADSsrise 1.1% in after-hours trading in New York.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183919949","content_text":"DiDi stock dropped 2% in premarket trading. DiDi posted Q3 net loss attributable to ordinary shareholders of RMB 30.6B (US$4.7B) in its Q3 earning report.DiDi Q3 adjusted EBITA was a loss of RMB 7.5B (US$1.2B), after posting Q2 adjusted EBITDA loss of RMB 2.3B.Core platform transactions for Q3 were 2.86B vs. 3.00B in Q2, with transactions for its China Mobility segment at 2.36B vs. 2.57B in the prior quarter. Transactions for the International segment were 499M.Q3 core platform gross transaction value reached RMB 68.7B (US$10.7B), down from $MB73.3B in Q2; GTV from the China Mobility segment of RMB 58.4B (US$9.1B) slipped from RMB 64.6B in Q2.Q3 total revenue of RMB 42.7B (US$6.6B), dropped from RMB 48.2B in Q2, with revenue from China Mobility at RMB 39.0B (US$6.1B) vs. RMB 44.8B in Q2 2021.The company also said it will schedule a shareholders meeting for a vote on choosing another internationally recognized stock exchange for listing shares that will convert from its ADSs, which now trade on the NYSE. On Dec. 3, DiDi's (DIDI) board said it would delist its ADSs from the NYSE.The company also announced changes to its board.DiDi (DIDI) ADSsrise 1.1% in after-hours trading in New York.","news_type":1},"isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841404284,"gmtCreate":1635930820035,"gmtModify":1635931302291,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>For two days the price make a full bounce![思考]&nbsp;","listText":"<a href=\"https://laohu8.com/S/00667\">$CHINA EAST EDU(00667)$</a>For two days the price make a full bounce![思考]&nbsp;","text":"$CHINA EAST EDU(00667)$For two days the price make a full bounce![思考]","images":[{"img":"https://static.tigerbbs.com/794798b338d076521ce105f8c83792ba","width":"1080","height":"3204"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841404284","isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}